Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5′6-Dimethylxanthenone-4-acetic Acid (Vadimezan)*
Open Access
- 2 April 2010
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 285 (14), 10553-10562
- https://doi.org/10.1074/jbc.m109.065631
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Systemic Blockade of Transforming Growth Factor-β Signaling Augments the Efficacy of Immunogene TherapyCancer Research, 2008
- Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerBritish Journal of Cancer, 2008
- A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activationThe EMBO Journal, 2007
- The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axisThe Journal of Experimental Medicine, 2007
- Role of TLR4 Tyrosine Phosphorylation in Signal Transduction and Endotoxin TolerancePublished by Elsevier BV ,2007
- Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptideBiochemical Journal, 2007
- Inhibition of p38 MAP kinase‐and RICK/NF‐κB‐signaling suppresses inflammatory bowel diseaseThe FASEB Journal, 2004
- Nod1 Detects a Unique Muropeptide from Gram-Negative Bacterial PeptidoglycanScience, 2003
- The Origin of the Synergistic Effect of Muramyl Dipeptide with Endotoxin and PeptidoglycanPublished by Elsevier BV ,2002
- Phase I Clinical and Pharmacokinetic Trial of Flavone Acetic AcidJNCI Journal of the National Cancer Institute, 1991